

METHODOLOGY ARTICLE

Open Access

# A simple knowledge-based mining method for exploring hidden key molecules in a human biomolecular network

Shingo Tsuji<sup>1,2</sup>, Sigeo Ihara<sup>1</sup> and Hiroyuki Aburatani<sup>1\*</sup>

## Abstract

**Background:** In the functional genomics analysis domain, various methodologies are available for interpreting the results produced by high-throughput biological experiments. These methods commonly use a list of genes as an analysis input, and most of them produce a more complicated list of genes or pathways as the results of the analysis. Although there are several network-based methods, which detect key nodes in the network, the results tend to include well-studied, major hub genes.

**Results:** To mine the molecules that have biological meaning but to fewer degrees than major hubs, we propose, in this study, a new network-based method for selecting these hidden key molecules based on virtual information flows circulating among the input list of genes. The human biomolecular network was constructed from the Pathway Commons database, and a calculation method based on betweenness centrality was newly developed. We validated the method with the ErbB pathway and applied it to practical cancer research data. We were able to confirm that the output genes, despite having fewer edges than major hubs, have biological meanings that were able to be invoked by the input list of genes.

**Conclusions:** The developed method, named NetHiKe (Network-based Hidden Key molecule miner), was able to detect potential key molecules by utilizing the human biomolecular network as a knowledge base. Thus, it is hoped that this method will enhance the progress of biological data analysis in the whole-genome research era.

**Keywords:** Knowledge-based analysis, Network data mining, Omics data analysis, Cancer research

## Background

The emergence of next-generation sequencing technology and sophisticated microarray technology has enhanced the diversity of high-throughput biological experiments. In addition to gene expression profiling, epigenetic data, including DNA methylation and histone modifications, and mutation analysis in cancer have been studied comprehensively in a genome-wide manner. It is absolutely indispensable to use biological knowledge-based analysis methods to translate the results of these experiments into a better understanding of the underlying phenomena and to plan the next stages of research.

Biological knowledge, such as pathways or gene sets, is compiled in various databases. In these databases, biological knowledge is represented as a precompiled, divided set of genes, such as the “P53 signaling pathway” or “apoptotic signaling pathway”. These pathways are utilized by various knowledge-based analysis methods. Over-representation analysis (ORA) is a widely used method for mapping a list of genes onto these pathways automatically, and this technique can determine the pathways or functional gene sets that are enriched in a given list of genes obtained experimentally. ORA is frequently implemented as a web application, such as the NCI-Nature Pathway Interaction Database [1,2] and the DAVID bioinformatics resources [3], that receive an input list of genes and calculate the p-values based on the frequency of the appearance of the

\*Correspondence: haburata-tyk@umin.ac.jp

<sup>1</sup>Genome Science Division, Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan

Full list of author information is available at the end of the article

input genes in each precompiled gene set. However, using the ORA methodology, the input list of genes is simply characterized with respect to the already-known pathways. Thus, researchers can rarely discover something new related to their input.

Another type of knowledge-based analysis is the network-based analysis method, which uses an interaction network of biomolecules as the knowledge. In this type of network, the biomolecules (proteins or genes) correspond to the nodes, and the edges indicate the relationships between the molecules (e.g., “protein A induces protein B” or “protein B phosphorylates protein C”). The assembled network is often called a protein-protein interaction (PPI) network or a biomolecular network, and several methodologies are available for analyzing experimental results using this network-based biological knowledge [4-6]. Many network-based analysis methods extract modules, which are sets of tightly connected nodes consisting of the input genes, and it is strongly expected that the genes in a module achieve a biological function in a coordinated manner. In addition, these modules sometimes include nodes that were not present in the input list. Thus, the network-based analysis methods partially overcome the disadvantages of ORA, in terms of the limitation to the predefined pathways or gene sets. However, these module-centric methods restrict the results of the analysis to a certain area of each module, even though the input genes are spread over the whole biomolecular network. Furthermore, when the modules of the analysis results become larger or more complex, it is almost impossible to understand their biological meanings.

Consequently, it would be beneficial to identify the nodes in the network as the key molecules that are relevant to the input list of genes. One of the most prominent characteristics of a node in a network is its degree, or number of neighbors. However, the degree contains information only about its neighbors, and in a similar way, other network measures, such as the clustering coefficient and assortativity, merely reflect the situations of their neighbors [7]. In contrast, certain node centralities can determine the importance of each node in a network by taking into consideration the topology of the entire network. Although there are various types of centralities, such as degree centrality, closeness centrality, eigenvector centrality, betweenness centrality and others, it is known that almost all of the centralities correlate with the degree of the node [8]. Partially because the role of hub nodes in biomolecular networks still remains an intensive research target [9-11], the methods based on these centralities [12-14] tend to produce analysis results that are biased toward major hub nodes.

In this study, we present a new network-based method for identifying the hidden key molecules, a description that indicates that the molecules are biologically relevant

to the input but do not have as many neighbors as the major hub nodes have. We have developed a centrality measure derived from betweenness centrality [15,16], named node-limited betweenness centrality (nlBC). First, we validated the method using a well-known pathway, the ErbB (EGFR) signaling pathway. Next, we applied it to a practical cancer mutation dataset and explored the availability of our method.

## Results and discussion


### Methodology overview

Figure 1 shows a schematic view of our method. We call this method Network-based Hidden Key Molecule Miner (NetHiKe), and a detailed description is provided in the “Methods” section. First, we constructed a biomolecular network as an undirected graph, which represents the knowledge about the interactions among the biomolecules (genes or proteins) using Pathway Commons data. Then, we projected the input genes onto the network and calculated the newly developed centrality values of the nodes. To calculate the centrality, we used only the shortest paths that have both ends in the set of the input nodes. Thus, the only nodes that were included in the network consisted of the shortest paths between all the possible combinations of any two input nodes with the centrality values. We named this centrality value the “node-limited betweenness centrality (nlBC)”, and this method can utilize the sum of the weight values of both ends of each shortest path (see “Methods” for details). The significance of the nlBC was assessed by p-values based on a Monte-Carlo simulation, by generating the same number of randomly selected nodes as the input nodes.

### Verification of the Method

First, we conducted the following computational experiments to verify whether the developed method has the ability to extract the appropriate knowledge related to the input data. As with the input data, we used a gene list that consisted of 10 ligands and 30 transcription factors of the ErbB pathway (listed in Additional file 1, and see “Methods” for details). The results of this analysis are listed in Table 1. This table contains the list of 31 genes whose simulated p-values were under 0.05, in ascending order of the p-values. The list also indicates the degree of the node in the background network, nlBC, and whether the gene was included in the input list.

The output list includes all four transmembrane tyrosine kinase receptors: the epidermal growth factor receptor (EGFR; also known as ERBB1), ERBB2, ERBB3 and ERBB4. These four receptor genes were not included in the input; NetHiKe successfully detected these four key molecules, which were deeply relevant to the 10 ligands in the input list. The transcription factors of the ErbB



pathway, such as Jun, E2F, STAT and MEF2, are presented in Table 1, and these factors were included in the input list. This observation means that NetHiKe can mark a molecule as key even when the node is in the input list. The network view of this result is shown in Figure 2. This figure contains all of the pairs of the shortest paths among the inputs. In this figure, we can verify that NetHiKe appropriately detected ErbB pathway related genes, such as FOXO4 and CREBBP.

To confirm the biological meanings of the results, we analyzed the genes in Table 1 using the Pathway Interaction Database, which is one of the typical over-representation analysis methods (see “Methods” for details). As shown in Additional file 2A (the link to NetHiKe), we obtained “E2F transcription factor network” as the most significant pathway, which is one of the downstream effects of an ErbB pathway stimulus.

#### **The relationship between nIBC and P-values**

To illustrate the properties of the nIBC and its p-values, we constructed individuals scatter plots for the nIBC, degree and p-value for the genes listed in Table 1 (Additional files 3A to 3C). The nIBC values modestly

correlate with degree (Additional file 3A), whereas the p-value has almost no relationship with degree or nIBC (Additional files 3B and 3C). To understand the behavior of nIBC and its p-value and to determine the robustness of nIBC, we constructed a boxplot to visualize the nIBC values for the genes in Table 1 (Additional file 3D and 3E). In the plots, the boxes of Additional file 3D show the nIBCs that were generated using randomly selected genes for calculating simulated p-values, and the vertical spread of the boxes are indicative of the variation of the nIBC in response to the various input list of genes. The boxes of Additional file 3E were generated by a leave-one-out method using the ErbB input genes, and the boxes are indicative of the robustness of the nIBC for certain input genes. The nIBC values vary in the different input list and their ranges also differ from each other. It seems that the ranges depend on the degree of each gene. However, the nIBC values of a certain semantic group of genes, such as those in the ErbB pathway, are significantly different from their randomly generated background distributions. Furthermore, the values are robust. Thus, to identify these alterations in the nIBC using NetHiKe, we validated the importance of the genes using simulated p-values instead of the nIBC values themselves.

**Table 1 The results of the ErbB pathway analysis**

Gene symbol	Degree	nIBC	Included in the input	Simulated p-value
EGFR	129	0.248	no	$5.01 \times 10^{-5}$
JUN	90	0.0854	yes	$1.17 \times 10^{-3}$
CREBBP	124	0.0919	no	$1.42 \times 10^{-3}$
TCF3	24	0.0431	no	$1.59 \times 10^{-3}$
FOXO4	9	0.00429	no	$2.62 \times 10^{-3}$
EP300	146	0.102	no	$2.70 \times 10^{-3}$
ERBB2	33	0.0274	no	$6.05 \times 10^{-3}$
CDC25A	18	0.0149	no	$8.28 \times 10^{-3}$
CABIN1	8	0.0369	no	$9.42 \times 10^{-3}$
ERBB3	13	0.0329	no	$9.76 \times 10^{-3}$
TFDP2	4	0.0039	no	$1.12 \times 10^{-2}$
CEBPB	34	0.0261	no	$1.18 \times 10^{-2}$
BAG1	13	0.00881	no	$1.19 \times 10^{-2}$
ID2	17	0.0318	no	$1.28 \times 10^{-2}$
MEF2D	11	0.00573	yes	$1.34 \times 10^{-2}$
MYBL2	13	0.0445	no	$1.44 \times 10^{-2}$
ERBB4	19	0.0304	no	$1.74 \times 10^{-2}$
SP1	59	0.0288	no	$1.92 \times 10^{-2}$
RB1	92	0.061	no	$2.02 \times 10^{-2}$
HCFC1	26	0.0352	no	$2.11 \times 10^{-2}$
RYBP	13	0.0155	no	$2.12 \times 10^{-2}$
E2F4	21	0.00537	yes	$2.31 \times 10^{-2}$
USP7	42	0.0606	no	$2.41 \times 10^{-2}$
SRF	26	0.0427	no	$2.85 \times 10^{-2}$
TFDP1	14	0.00927	no	$2.96 \times 10^{-2}$
RBL2	25	0.00674	no	$3.01 \times 10^{-2}$
STAT1	50	0.026	yes	$3.06 \times 10^{-2}$
E2F1	45	0.0282	yes	$3.31 \times 10^{-2}$
ATF2	27	0.00428	no	$4.78 \times 10^{-2}$
CEBPA	21	0.00393	no	$4.89 \times 10^{-2}$
YWHAQ	63	0.0189	no	$4.93 \times 10^{-2}$

Key molecules (genes) with simulated p-values less than 0.05 are listed in the order of ascending p-values. The degree is the number of edges (number of interaction partners), and the fourth column indicates whether the gene was included in the input list of genes.

### Comparison with the Hubba results

To clarify the characteristics of our methods, we compared our results with the existing method. As a comparison method, we chose Hubba [12] (see “Methods” for details). We compared the top 30 genes from the NetHiKe results, chosen based on their p-values, and the Hubba results, which were produced by the six different algorithms that are implemented in Hubba. Figure 3A shows a Venn diagram of this comparison. The Hubba results


have more genes than the NetHiKe results. This discrepancy occurs because the Hubba results consist of a union of the six different outputs (all of the genes are listed in Additional file 4). As shown in Additional files 2B to 2F, the Hubba results from the six different methods include ErbB pathway-related genes, such as “Glucocorticoid receptor regulatory network” and “Regulation of nuclear SMAD2/3 signaling”. This observation means that the results of Hubba also have an important role in the analysis of the ErbB pathway.

When drawing the boxplots for the degrees of the genes (Figure 3B), the degree distribution of the NetHiKe results was much smaller than that of the Hubba results excluding DMNC, one of the algorithms of Hubba. For example, EGFR (ERBB1), ERBB2, ERBB3, and ERBB4, which are four membrane receptors of the ErbB pathway, have 129, 33, 13, and 19 neighbors, respectively, in the background knowledge-base network. EGFR is considered to be one of the major hubs in this network, and Hubba (DMNC), whose degree distribution was as small as that of NetHiKe, failed to detect EGFR. In contrast, only the NetHiKe result has all four of these receptors in the top 30 gene list. Recently, ERBB2 and ERBB3, which have fewer degrees than EGFR, have been considered to play key roles in cancer tissue [17,18]. These results suggest that NetHiKe can detect the hidden key molecules based on the context in which an input list of genes is given.

### Weighted inputs

Finally, we have validated the function for handling the weighted values of the input nodes. The weight of NRG2, which is one of the input genes in this validation study, was set to 2.0, and the remainder of the input nodes had their weight values set to 1.0. The results of the analysis are shown in table format in Additional file 5. Overall, there were many overlaps between the NRG2 weighted results and the non-weighted results, such as JUN, TCF3, CREBBP and EP300 (Additional file 5A and Table 1). This observation could also be confirmed by the results of an analysis using the Pathway Interaction Database (Additional files 2A and 2G). The network visualization near ERBB receptor family is shown in Figure 4. We can confirm that the red color of ERBB3 and ERBB4 is deeper than that of Figure 1, which was produced using the non-weighted input list. This finding means that the p-values of these genes became more significant, with p-values less than 0.05 to 0.01, and the results were satisfactory considering that NRG2 is the ligand for ERBB3 and ERBB4, not for ERBB1 and ERBB2 [19].

When the weight value of NRG2 was increased to 20.0, the results included more ERBB4-related genes (the result table is shown in Additional file 5). To confirm this finding, we again examined the results using the Pathway Interaction Database. As shown in Additional file 2H,




“ERBB4 signaling events” was the second most important pathway because the increased weight of NRG2, the ligand of ERBB4, appropriately enhances the importance of ERBB4-related pathways. Taking these results together, if appropriate weights are given to NetHiKe, this algorithm can detect the nodes that have biological meaning but do not have many edges with statistical significance, such as  $p < 0.01$ .

#### Analysis of practical cancer mutation data

We applied the NetHiKe algorithm to the list of genes that are somatically mutated in glioblastomas using their observed mutation frequencies as the weight values. The input mutation data were obtained from The Cancer Genome Atlas (TCGA) website (see the “Methods”


for details about TCGA and glioblastoma). The analysis results are shown in Table 2 and Additional file 6. The genes with p-values less than 0.01 are listed in Table 2, and the whole network is visualized in Additional file 6. In Additional file 6, PTEN, TP53 and EGFR have a thicker blue border than the other genes because they have an extremely high mutation rate in glioblastomas. (See Additional file 1 for the numerical data).

As shown in Table 2, the NetHiKe results do not include several famous key players in glioblastoma biology, such as EGFR, SRC and TP53 [20]. However, the nodes with fewer edges than those above that are included also have implications in glioblastoma biology. PTK2 (also known as FAK: focal-adhesion kinase), which is the top-ranked gene in Table 2, is a non-receptor tyrosine kinase protein that serves as a major mediator of cell migration [21], and the



NetHiKe results

Hubba results (6 algorithms)




**Figure 3 Comparison of the results of NetHiKe and Hubba.** **A)** Venn diagram for the comparison of the results of NetHiKe and Hubba. The Hubba result is the combination of the six different methods. **B)** The boxplot of the degree of each node. The degree was calculated in the background network rather than in the extracted network.

suppression of PTK2 phosphorylation inhibits glioma cell migration [22]. PTK2 is also gaining attention as a drug target in cancer therapy; for example, a kinase inhibitor of PTK2 has been developed in ovarian cancer [23]. Clinical studies on pancreatic cancer [24] and neuroblastoma [25], which is the most common childhood brain cancer, are also under way. PXN (also known as Paxillin), which is one of the hidden key molecules (Table 2), is known to be a downstream target of PTK2. Additionally, the PTK2(FAK)-signaling pathway, which is formed by these genes, has been shown to be upstream of AKT-signaling in promoting malignant behaviors of high-grade gliomas [26]. BCAR1 (also known as p130Cas), which is the second

most significant key molecule, is also known to be a mediator of growth factor-dependent migration through tyrosine phosphorylation in glioma cells [27].

Figure 5 shows the neighbor nodes of PTK2, which were extracted and visualized by Cytoscape, and this figure shows that PTK2 associates not only with PXN but also with BCAR1. Although the role of the relationship between PTK2 and ITGB3 in glioma biology is not clear, ITGB3 (integrin  $\beta$ 3) plays a pro-apoptotic role in glioma cells, and it is related to anti-cancer drug resistance [28]. These results suggest that NetHiKe can detect the molecules that are deeply related to the biological background of the brain tumor.





### Comparison to Hubba

We compared the NetHiKe results with the Hubba results as an existing similar method. Because Hubba cannot manipulate the node weights, we used only the gene names as an input for Hubba with the six different algorithms, as in the ERBB comparison case (see the


**Table 2 The results of GBM mutation data**

Gene symbol	Degree	nIBC	Included in the input	Simulated p-value
PTK2	20	0.014	no	$5.02 \times 10^{-5}$
BCAR1	17	0.00496	yes	$1.52 \times 10^{-3}$
CD36	11	0.00336	no	$2.15 \times 10^{-3}$
PIK3CB	10	0.00525	no	$2.70 \times 10^{-3}$
MAP2	6	0.00223	no	$3.81 \times 10^{-3}$
DHFR	4	0.00318	no	$4.62 \times 10^{-3}$
VAV3	11	0.00483	no	$5.44 \times 10^{-3}$
ITGB3	37	0.0273	yes	$5.83 \times 10^{-3}$
SP3	9	0.00678	no	$6.44 \times 10^{-3}$
TXN	8	0.00692	no	$6.83 \times 10^{-3}$
DAP3	8	0.00269	no	$7.22 \times 10^{-3}$
RUNX2	22	0.0111	no	$7.78 \times 10^{-3}$
NR2F1	8	0.0239	no	$8.61 \times 10^{-3}$
PXN	45	0.0198	no	$8.85 \times 10^{-3}$
RPS27L	9	0.00121	no	$9.09 \times 10^{-3}$
PTPN1	33	0.018	no	$9.50 \times 10^{-3}$

The table shows the key molecules ( $p < 0.01$ ) that were inferred by NetHiKe, with their degrees and nIBC values. The genes are ordered by their simulated p-values.

“Methods” for the details). Additional file 7 shows the top 16 genes of the six Hubba methods, which represents the same number of genes found in the NetHiKe results with  $p < 0.01$ . There were no overlapping genes between the NetHiKe results and the Hubba results. In contrast, there were several overlapping genes among the six Hubba methods. When we mapped the differentially expressed genes in glioblastoma obtained from TCGA to these results, the genes were distributed across all of the results from both NetHiKe and Hubba. This observation could indicate that the listed genes of both methods are related to glioblastoma biology. For example, MAP2, which was selected by NetHiKe and is differentially expressed in glioma, is known to be one of the neuronal differentiation markers, and its expression level is naturally decreased in brain tumors [29].

Table 3 shows the genes that were presented at least three times in all six methods of generating Hubba results. Obviously, the genes selected by Hubba have much greater degrees than the genes selected by NetHiKe (Additional file 7, also Tables 2 and 3). Many of the genes selected by Hubba are known to be major key players in glioma biology, such as EGFR, EP300, SRC and TP53 [20]. Although the NetHiKe results tend to have fewer degrees, they have relationships to these major genes to a certain extent. For instance, SRC and TP53, which were selected in the Hubba results many times, are presented in Figure 5 as the neighbors of PTK2. RAC1 and SHC1, which were also selected by Hubba (Additional file 7), associate with PTK2 (Figure 5), and the association between SHC1 and PTK2 has been known for a long time [30].



**Figure 5 PTK2 and its neighbors.** The network visualization of PTK2 and its neighbor nodes with input weight values (thickness of blue border line) and P-values (depth of red color). PTK2 has a direct relationship with BCAR1 and PXN, as well as TP53, which is well-known to be one of the most famous hub genes.

Therefore, these results show that NetHiKe captures the nodes that are on the periphery of the major hub nodes. We think that this outcome arises because nlBC includes only the shortest paths with both ends in the input nodes. This characteristic reduces the shortest paths that are concentrated on the major hubs with no relationships to the input genes. Consequently, NetHiKe is able to mine the hidden key molecules that have sufficient biological meaning and fewer degrees than the major hub nodes.

## Conclusions

We have proposed an analysis method, Network-based Hidden Key Molecule Miner (NetHiKe), which can extract limited numbers of hidden key molecules relevant to genes provided as input, using a human biomolecular network. NetHiKe comprises three steps: mapping the input genes onto the network, a node-limited

betweenness centrality (nlBC) calculation, and validation of the statistical significance by simulated p-values. NetHiKe tends to capture the nodes with fewer degrees than major hub nodes, which are usually intensive research targets. We have confirmed that NetHiKe's outputs contain sufficient biological information and that the input node weights appropriately produce a change in the results based on the biological meanings. Furthermore, with the glioblastoma analysis, we demonstrated that NetHiKe can be used for analyzing practical biology data produced by genome-wide experimental methodologies.

The present knowledge about cell biology is enormous, and thus, the derivation of informative meaning from genome-wide experimental results is urgently needed. We anticipate that this simplicity will contribute to additional striking insights into cellular activity and help researchers to determine future research directions.

## Methods

### Biomolecular network

We used the Pathway Commons [31] dataset, released on Oct 27, 2011, to construct a human biomolecular network. Pathway Commons currently includes the following nine data sources: BioGRID [32], The Cancer Cell Map [33], the HPRD [34], HumanCyc [35], the databases of the Systems Biology Center NewYork [36], IntAct [37], the Molecular Interaction Database (MINT) [38], the NCI-Nature Pathway Interaction Database [1] and Reactome [39]; thus, it includes many types of biomolecular interactions, such as biochemical reactions, complex assembly, transport and catalysis events, and physical interactions involving proteins, DNA, RNA, small molecules and complexes.

We visualized the degree distribution of the network that was constructed from the pathway commons data

**Table 3 The summary of the Hubba results for GBM data**

Gene	Degree
EGFR	129
EP300	146
HSP90AA1	166
HSPA8	111
PRKDC	112
SHC1	110
SRC	134
TP53	132
YWHAG	183

The genes that were represented at least three times among the results of the six different Hubba algorithms.



(Additional file 8A), and we found that there were extra high-degree nodes, which disturb the power-law of the log-log degree distribution. To obtain a more reliable biomolecular network, we extracted the binary relationships of biomolecules that represented at least two of the nine data sources used by the Pathway Commons. Again, we visualized the degree distribution of this edge-selected network; the distribution now followed the power-law clearly (Additional file 8B). We used this network in further analyses.

In a network construction step, redundant edges and self-directed edges may exist if multiple data sources include the same interaction or a multimeric protein complex. Because the nlBC algorithm described below does not take into account multiple edges or self-directed edges, all of the redundant edges were collapsed into single edges, and all of the self-directed edges were pruned from the network. Consequently, by ignoring the tiny disconnected components, we obtained a human biomolecular network: a connected, unweighted, undirected graph with 7,456 nodes and 35,553 edges.

#### Node-limited betweenness centrality

A biomolecular network can be described as a graph  $G = (V, E)$ , where the set  $V$  of nodes represents proteins or genes, and the set  $E$  of edges represents the relationships among these biomolecules. Let  $\sigma_{st}$  denote the number of shortest paths from the node  $s \in V$  to the node  $t \in V$ , and let  $\sigma_{st}(v)$  denote the number of shortest paths from  $s$  to  $t$  that include  $v$ . The betweenness centrality of node  $v$  is determined as follows:

$$BC(v) = \sum_{s \neq v \neq t \in V} \frac{\sigma_{st}(v)}{\sigma_{st}}.$$

The betweenness centrality of a node can be calculated by counting the number of shortest paths passing through the node and the entire number of shortest paths between arbitrary pairs of nodes in the graph.

Normally, the betweenness centrality of a node is calculated based on all of the nodes in the graph. However, in this study, as we wanted to identify the nodes that have a close relationship to the input nodes, we developed a novel variant of betweenness centrality, named “node-limited betweenness centrality,” to mine the hidden key molecules from among the whole background network. The variant method includes only the shortest paths for which both ends are in the input nodes. In addition, the method can manipulate the weights of both ends.

Let  $U$  be the set of the input nodes; then, we can define the subgraph  $H = (V_H, E_H)$  as follows:

$$H = \bigcup_{s \neq t \in U} SP_{<s,t>}.$$

$SP_{<s,t>}$  denotes a path set of all the possible shortest paths from node  $s$  to node  $t$ . Node-limited betweenness centrality (nlBC) can have non-zero values when the node  $v$  satisfies the condition  $v \in V_H$ , and the definition of this term is as follows:

$$nlBC(v) = \frac{1}{w} \sum_{s \neq t \in U} (w(s) + w(t)) \frac{\sigma_{st}(v)}{\sigma_{st}}.$$

$$w = \sum_{s \neq t \in U} w(s) + w(t)$$

$w(x)$  is the weight value of the node  $x$ . Under the definition of nlBC, we can define the subgraph  $H$  that connects all of the input nodes as a set of shortest paths, and we extracted this subgraph to visualize the results and compare NetHiKe with other methods.

#### Evaluating statistical significance

To estimate the statistical significance of the nlBC values of each node, we used a Monte Carlo simulation. The same number of nodes as that on the input list was randomly sampled from the network, and the nlBC values of these nodes were calculated. After we obtained the node weight values, the weights were randomly mapped to the selected nodes. Repeating this procedure yielded an empirical distribution of the nlBC values, and we were able to calculate the simulated p-value using this distribution. Let  $n$  be the number of times the simulation is repeated and let  $r$  be the number of replicates obtained that have the centrality values  $\geq nlBC_{original}(v)$ . The simulated p-value of node  $v$  ( $P_v$ ) is given as follows [40]:

$$P_v = \frac{r + 1}{n + 1}.$$

In this study, we set  $n = 20,000$ , and the simulation count can be controlled by one of the program options.

#### ErbB signaling pathway

The ErbB signaling pathway plays an important role in cell growth and cancer development [19,41]. Although the complete function of the pathway remains unknown, the ErbB signaling pathway is usually represented by the four transmembrane tyrosine kinase receptors (ERBB1 to ERBB4), several ligands of the receptors, various types of transcription factors and the complex signaling network between the receptors and the transcription factors (for example, see [42] or other pathway databases available on the web). We selected 10 ligands and 30 transcription factors from the ErbB pathway (see Additional file 1), and these molecules represent the entrance and the exit of the information flows through the pathway. In the first step of the validation, the weights of the genes were set to 1.0, and in the later step, the weight of NRG2 was calibrated from 2.0 to 20.0 for the methodology verification.

## Visualization

Although visualizing a network that includes a large number of nodes is often difficult, it is important for understanding the relationships among the nodes of interest. In this study, we visualized only the key molecules and the input genes with the subgraph containing the nodes connecting them (e.g., Figure 2). We used Cytoscape2.8.2 [43] for visualizing the network, and the Spring Embedded layout option was applied to the network to provide an overview of the relationships between the input nodes and the key molecules. For this visualization, the NetHiKe software produces input files for Cytoscape were as follows: background network information (.sif) and node attributes (.noa).

## The pathway interaction database

The Pathway Interaction Database [1,2] is a curated collection of information about known biomolecular interactions and key cellular processes assembled into signaling pathways. The database also has a web-based pathway search interface. Once the gene list is uploaded to the database, it calculates the p-values for each pathway, depending on the number of input genes that are included in the pathway. The functions of the input genes can be estimated through the output pathways with p-values; thus, we used it as a typical over-representation analysis (ORA) to grasp the approximate meanings of the input list of genes.

## Hubba

Hubba [12] is one of the most widely used network analysis programs in the molecular biology area, and we can use it through the web interface or Cytoscape plug-in. Hubba takes a network as the input data and can evaluate the importance of nodes via various methods. In this study, we used the following six methods: degree, BottleNeck, Edge Percolation Component (EPC), Maximum Neighborhood Component (MNC), Density of Maximum Neighborhood Component (DMNC), and betweenness centrality. To import our data into Hubba, we extracted the sub-network that consists of all pairs of shortest paths connecting all of the input nodes.

## GBM data from TCGA

With the recent advances in next-generation DNA sequencing technology, comprehensive cancer genome analyses are now underway [20,44]. The Cancer Genome Atlas (TCGA) is a large-scale collaborative effort to systematically characterize the genomic changes that occur in cancer by applying genome analysis technologies. TCGA is designed to target many types of cancer and to characterize various genomic changes in cancer, including somatic mutation, mRNA and miRNA expression, methylation aberration and so on. Among these data

sets, glioblastoma multiforme (GBM), which is one of the most aggressive types of primary brain tumor, has been analyzed since the early stages of TCGA history. The list of genes used for this analysis was downloaded from TCGA data browser website on the TCGA data portal [45]. The TCGA data browser website has a user-friendly interface for downloading lists of genes matching many types of search conditions from the accumulated TCGA experimental results.

## Somatic mutation data

Using the Data Portal web of TCGA, we obtained the somatic mutated genes for the following conditions: for “Disease Type”, we selected “GBM Glioblastoma multiforme”; for “Validated Somatic Mutations”, we selected “any non-silent-validated” and for Frequency  $\geq 1.0\%$ , we used the default value of the setting. We filtered out the genes that were analyzed in a small number ( $< 100$ ) of samples and used the mutation ratio (percentage) as the weight of each gene (Additional file 1, sheet “GBM\_analysis”).

## Expression data

In the TCGA Data Portal site, we downloaded the list of differentially expressed genes in GBM with the following conditions: “AgilentG4502A\_07 log2 tumor/normal ratio” was selected for “Gene Expression”; the ratio values were set between -1.2 and 1.2, and Frequency was over 40 percent. The resulting list is available as the second sheet of Additional file 7.

## Software availability

The NetHiKe software is written in C++ and Python and is available at the following website. <http://tsjshg.bitbucket.org/nethike>.

Because it requires considerable system memory (4 GB or more), this software should be run on a 64-bit system.

## Additional files

**Additional file 1:** The input gene list of the ErbB pathway and GBM analysis. Two input gene lists were used for this study. One contains the ligands and transcription factors from the ErbB pathway, and the other contains the mutated genes in GBM with the frequencies as the weights. (<http://www.microsoft.com/download/en/details.aspx?id=10>).

**Additional file 2:** The collection of results for the Pathway Interaction Database analysis. The index.html file contains the links to the Pathway Interaction Database results for the various input genes. The input genes consist of the results of NetHiKe and Hubba (the top 30 genes of each). (Mini-websites, browse the index.html).

**Additional file 3:** Degree, P-value, and nIBC for the ErbB pathway analysis data. Plots of the degrees, p-values, and nIBC values of genes with  $P < 0.05$  in the results of the ErbB pathway analysis (A-C) and boxplots of the nIBC values (D and E). A) Plot of the node degrees in the background

network vs. nIBC. B) Degree vs. simulated p-values. C) nIBC vs. p-values. D) Boxplot visualization of the genes in Table 1. The boxes are the nIBC values generated from randomly selected genes to calculate the simulated p-values, and the yellow dots denotes the actual nIBC value that was calculated based on the input genes (listed in the Additional file 1). The simulated p-values, listed in the Table 1, are plotted as the red line associated with the right axis. E) The nIBC values that were generated by a leave-one-out method using the input genes, and the actual nIBC values as the yellow dots. The plot D and E have the same Y-axis scale (left) and the gene order in X-axis.

**Additional file 4: Comparison lists of the top 30 genes on NetHiKe and Hubba.** The lists of the top 30 genes generated by NetHiKe and Hubba with the same input data. In the Hubba analysis, six different methods were used. The six-digit number indicates the Pathway Commons ID, as the molecules do not have general gene names.

**Additional file 5: The NetHiKe results of the weighted NRG2.** The sheet named "NRG2\_weighted\_2.0" is the NetHiKe result of the input with the NRG2 weight set to 2.0, and "NRG2\_weighted\_20.0" is the result with the NRG2 weight set to 20.0. The genes with p-values less than 0.05 are listed. (<http://www.microsoft.com/download/en/details.aspx?id=10>)

**Additional file 6: The GBM network and key molecules inferred by NetHiKe.** The extracted network made by genes mutated in GBM. The blue-bordered nodes are the input nodes, and the p-values are shown by the depth of the red color.

**Additional file 7: The comparison of the GBM analysis results between NetHiKe and Hubba.** The sheet named "NetHiKe and Hubba results" contains the top 16 genes that were  $p < 0.01$  in the NetHiKe analysis and the same number of top-ranked genes from the various Hubba methods. There are no overlapping genes between the NetHiKe results and the Hubba results. However, there are several overlapping genes among the various Hubba methods. The second sheet, named "GBM\_expression\_1.2\_ov40p," contains the downloaded data from the TCA website to clarify the differentially expressed genes in the GBM analysis. (<http://www.microsoft.com/download/en/details.aspx?id=10>).

**Additional file 8: Two different degree distributions depend on the edge selection.** Log-log degree distribution for the network constructed from the whole Pathway Commons data (A) and the selected edges (B).

## Abbreviations

GBM, Glioblastoma multiforme; nIBC, Node-limited betweenness centrality; NetHiKe, Network-based Hidden Key Molecule Miner; ORA, Over-representation analysis; PPI, Protein-protein interaction network; TCGA, The Cancer Genome Atlas.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

ST conceived the study, performed the statistical analysis, and wrote the paper. SI and HA participated in the study's discussions. HA helped to draft the manuscript. All of the authors read and approved the final manuscript.

## Acknowledgements

This work was supported by JSPS KAKENHI Grant Number 19650069 to S.T. and 24221011 to H.A.

## Author details

<sup>1</sup>Genome Science Division, Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan. <sup>2</sup>Komaba Open Laboratory, The University of Tokyo, Tokyo, Japan.

Received: 8 February 2012 Accepted: 25 July 2012

Published: 15 September 2012

## References

- Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH: **PID: the Pathway Interaction Database.** *Nucleic Acids Res* 2009, **37**:D674–D679.

- Pathway Interaction Database.** [<http://pid.nci.nih.gov/>]
- Huang daW, Sherman BT, Lempicki RA: **Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.** *Nat Protoc* 2009, **4**:44–57.
- Spirin V, Mirny LA: **Protein complexes and functional modules in molecular networks.** *Proc Natl Acad Sci USA* 2003, **100**:12123–12128.
- Georgii E, Dietmann S, Uno T, Pagel P, Tsuda K: **Enumeration of condition-dependent dense modules in protein interaction networks.** *Bioinformatics* 2009, **25**:933–940.
- Cerami E, Demir E, Schultz N, Taylor BS, Sander C: **Automated network analysis identifies core pathways in glioblastoma.** *PLoS ONE* 2010, **5**:e8918.
- Yamada T, Bork P: **Evolution of biomolecular networks: lessons from metabolic and protein interactions.** *Nat Rev Mol Cell Biol* 2009, **10**:791–803.
- Valente TW, Coronges K, Lakon C, Costenbader E: **How Correlated Are Network Centrality Measures?** *Connect (Tor)* 2008, **28**:16–26.
- Vallabhajosyula RR, Chakravarti D, Lutfeali S, Ray A, Raval A: **Identifying hubs in protein interaction networks.** *PLoS ONE* 2009, **4**:e5344.
- Agarwal S, Deane CM, Porter MA, Jones NS: **Revisiting date and party hubs: novel approaches to role assignment in protein interaction networks.** *PLoS Comput Biol* 2010, **6**:e1000817.
- Zotenko E, Mestre J, O'Leary DP, Przytycka TM: **Why do hubs in the yeast protein interaction network tend to be essential: reexamining the connection between the network topology and essentiality.** *PLoS Comput Biol* 2008, **4**:e1000140.
- Lin CY, Chin CH, Wu HH, Chen SH, Ho CW, Ko MT: **Hubba: hub objects analyzer—a framework of interactome hubs identification for network biology.** *Nucleic Acids Res* 2008, **36**:W438–W443.
- Wu J, Vallenius T, Ovaska K, Westermarck J, Makela TP, Hautaniemi S: **Integrated network analysis platform for protein-protein interactions.** *Nat Methods* 2009, **6**:75–77.
- Brohee S, Faust K, Lima-Mendez G, Sand O, Janky R, Vanderstocken G, Deville Y, van Helden J: **NeAT: a toolbox for the analysis of biological networks, clusters, classes and pathways.** *Nucleic Acids Res* 2008, **36**:W444–W451.
- Freeman L C: **A set of measures of centrality based on betweenness.** *Sociometry* 1977, **40**:35–41.
- Fortunato S, Latora V, Marchiori M: **Method to find community structures based on information centrality.** *Phys Rev E Stat Nonlin Soft Matter Phys* 2004, **70**:056104.
- Baselga J, Swain SM: **Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.** *Nat Rev Cancer* 2009, **9**:463–475.
- Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB: **Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.** *Sci Signal* 2009, **2**:ra31.
- Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS: **Epidermal growth factor receptor (EGFR) signaling in cancer.** *Gene* 2006, **366**:2–16.
- McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, Yung WK, Bogler O, Weinstein JN, VandenBerg S, Berger M, Prados M, Muzny D, Morgan M, Scherer S, Sabo A, Nazareth L, Lewis L, Hall O, Zhu Y, Ren Y, Alvi O, Yao J, Hawes A, Jhangiani S, Fowler G, San Lucas A, Kovar C, Cree A, Dinh H, Santibanez J, Joshi V, Gonzalez-Garay ML, Miller CA, Milosavljevic A, Donehower L, Wheeler DA, Gibbs RA, Cibulskis K, Sougnez C, Fennell T, Mahan S, Wilkinson J, Ziaugra L, Onofrio R, Bloom T, Nicol R, Ardlie K, Baldwin J, Gabriel S, Lander ES, Ding L, Fulton RS, McLendon MD, Wallis J, Larson DE, Shi X, Abbott R, Fulton L, Chen K, Koboldt DC, Wendt MC, Meyer R, Tang Y, Lin L, Osborne JR, Dunford-Shore BH, Miner TL, Delehaunty K, Markovic C, Swift G, Courtney W, Pohl C, Abbott S, Hawkins A, Leong S, Haipek C, Schmidt H, Wiechert M, Vickery T, Scott S, Dooling DJ, Chinwalla A, Weinstock GM, Mardis ER, Wilson RK, Getz G, Winckler W, Verhaak RG, Lawrence MS, O'Kelly M, Robinson J, Alexe G, Beroukheim R, Carter S, Chiang D, Gould J, Gupta S, Korn J, Mermel C, Mesirov J, Monti S, Nguyen H, Parkin M, Reich M, Stransky N, Weir BA, Garraway L, Golub T, Meyerson M, Chin L, Protopopov A, Zhang J, Perna I, Aronson S, Sathiamoorthy N, Ren G, Yao J, Wiedemeyer WR, Kim H, Kong SW, Xiao Y, Kohane IS, Seidman J, Park PJ, Kucherlapati R, Laird PW, Cope L, Herman

- JG, Weisenberger DJ, Pan F, Van den Berg, D, Van Neste L, Yi JM, Schuebel KE, Baylin SB, Absher DM, Li JZ, Southwick A, Brady S, Aggarwal A, Chung T, Sherlock G, Brooks JD, Myers RM, Spellman PT, Purdom E, Jakkula LR, Lapuk AV, Marr H, Dorton S, Choi YG, Han J, Ray A, Wang V, Durinck S, Robinson M, Wang NJ, Vranizan K, Peng V, Van Name E, Fontenay GV, Ngai J, Conboy JG, Parvin B, Feiler HS, Speed TP, Gray JW, Brennan C, Socci ND, Olshen A, Taylor BS, Lash A, Schultz N, Reva B, Antipin Y, Stukalov A, Gross B, Cerami E, Wang WQ, Qin LX, Seshan VE, Villafania L, Cavatore M, Borsu L, Viale A, Gerald W, Sander C, Ladanyi M, Perou CM, Hayes DN, Topal MD, Hoadley KA, Qi Y, Balu S, Shi Y, Wu J, Penny R, Bittner M, Shelton T, Lenkiewicz E, Morris S, Beasley D, Sanders S, Kahn A, Sfeir R, Chen J, Nassau D, Feng L, Hickey E, Barker A, Gerhard DS, Vockley J, Compton C, Vaught J, Fielding P, Ferguson ML, Schaefer C, Zhang J, Madhavan S, Buetow KH, Collins F, Good P, Guyer M, Ozenberger B, Peterson J, Thomson E: **Comprehensive genomic characterization defines human glioblastoma genes and core pathways.** *Nature* 2008, **455**:1061–1068.
21. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD: **FAK integrates growth-factor and integrin signals to promote cell migration.** *Nat Cell Biol* 2000, **2**:249–256.
22. Lin AH, Elceiri BP, Levin EG: **FAK mediates the inhibition of glioma cell migration by truncated 24 kDa FGF-2.** *Biochem Biophys Res Commun* 2009, **382**:503–507.
23. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK: **Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.** *Cancer Res* 2007, **67**:10976–10983.
24. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, Golubovskaya VM: **A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.** *Cell Cycle* 2009, **8**:2435–2443.
25. Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, Golubovskaya VM: **Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.** *Cell Cycle* 2010, **9**:1005–1015.
26. Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturvedi A, Mathews MS, Ro DI, Alkafef S, Hsu N, Hamamura M, Yu L, Hess KR, Tromberg BJ, Linskey ME, Zhou YH: **EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment.** *Mol Cancer* 2011, **10**:123.
27. Evans IM, Yamaji M, Britton G, Pellet-Many C, Lockie C, Zachary IC, Frankel P: **Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells.** *Mol Cell Biol* 2011, **31**:1174–1185.
28. Kim JH, Zheng LT, Lee WH, Suk K: **Pro-apoptotic role of integrin  $\beta 3$  in glioma cells.** *J Neurochem* 2011, **117**:494–503.
29. Tataro VM, Xiang C, Biegel JA, Dahmane N: **ZNF238 is expressed in postmitotic brain cells and inhibits brain tumor growth.** *Cancer Res* 2010, **70**:1236–1246.
30. Hecker TP, Grammer JR, Gillespie GY, Stewart J, Gladson CL: **Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples.** *Cancer Res* 2002, **62**:2699–2707.
31. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, Schultz N, Bader GD, Sander C: **Pathway Commons, a web resource for biological pathway data.** *Nucleic Acids Res* 2011, **39**(Database issue):D685–D690.
32. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M: **BioGRID: a general repository for interaction datasets.** *Nucleic Acids Res* 2006, **34**:D535–D539.
33. **The Cancer Cell Map.** [http://cancer.cellmap.org/cellmap/]
34. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A: **Human Protein Reference Database–2009 update.** *Nucleic Acids Res* 2009, **37**:D767–D772.
35. Karp PD, Ouzounis CA, Moore-Kochlacs C, Goldovsky L, Kaipa P, Ahrnén D, Tsoka S, Darzentas N, Kunin V, López-Bigas N: **Expansion of the BioCyc collection of pathway/genome databases to 160 genomes.** *Nucleic Acids Res* 2005, **33**:6083–6089.
36. **SBCNY.** [http://www.sbcny.org]
37. Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge A, Derow C, Feuermann M, Ghanbarian AT, Kerrien S, Khadake J, Kerssemakers J, Leroy C, Menden M, Michaut M, Montecchi-Palazzi L, Neuhauser SN, Orchard S, Perreau V, Roehert B, van Eijk K, Hermjakob H: **The IntAct molecular interaction database in 2010.** *Nucleic Acids Res* 2010, **38**:D525–D531.
38. Ceol A, Chatr Aryamontri A, Licata L, Peluso D, Briganti L, Perfetto L, Castagnoli L, Cesareni G: **MINT, the molecular interaction database: 2009 update.** *Nucleic Acids Res* 2010, **38**:D532–D539.
39. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, Garapati P, Hemish J, Hermjakob H, Jassal B, Kanapin A, Lewis S, Mahajan S, May B, Schmidt E, Vastrik I, Wu G, Birney E, Stein L, D'Eustachio P: **Reactome knowledgebase of human biological pathways and processes.** *Nucleic Acids Res* 2009, **37**:D619–D622.
40. Davison A, Hinkley D: **Chapter 4 Tests.** In *Bootstrap Methods and their Application.* New York: Cambridge University Press:1997.
41. Wheeler DL, Dunn EF, Harari PM: **Understanding resistance to EGFR inhibitors-impact on future treatment strategies.** *Nat Rev Clin Oncol* 2010, **7**:493–507.
42. **ErbB/HER Signaling (Cell Signaling Technology).** [http://www.cellsignal.com/reference/pathway/ErbB\_HER.html]
43. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T: **Cytoscape 2.8: new features for data integration and network visualization.** *Bioinformatics* 2011, **27**:431–432.
44. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S: **Diverse somatic mutation patterns and pathway alterations in human cancers.** *Nature* 2010, **466**:869–873.
45. **The Cancer Genome Atlas Data Portal.** [http://tcga-portal.nci.nih.gov/tcga-portal/AnomalySearch.jsp]

doi:10.1186/1752-0509-6-124

Cite this article as: Tsuji et al.: A simple knowledge-based mining method for exploring hidden key molecules in a human biomolecular network. *BMC Systems Biology* 2012 **6**:124.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

